BLFS is no longer listed. Its last trade on record was Oct 7, 2026. The price and figures on this page are from its last trading day and final filings, and are no longer updated.
Latest Ratios: P/E Ratio N/A · EV/EBITDA N/A · ROE N/A. (1995–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | — | $1.2B | $1.2B | $710M | $773M | $1.4B | $1.1B | $315M | $196M | $80M | $20M |
| Enterprise Value | — | $1.2B | $1.1B | $716M | $797M | $1.4B | $1.0B | $310M | $165M | $73M | $22M |
| P/E Ratio → | — | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | 12.23 | 14.54 | 9.37 | 10.14 | 12.04 | 22.65 | 11.50 | 9.91 | 7.22 | 2.47 |
| P/B Ratio | — | 3.16 | 3.43 | 2.10 | 2.12 | 2.99 | 5.31 | 3.79 | 4.53 | 7.89 | 6.43 |
| P/FCF | — | 2827.50 | 229.80 | — | — | — | 578.77 | 585.26 | 105.83 | 172.55 | — |
| P/OCF | — | 58.48 | 141.85 | — | — | — | 167.19 | 259.58 | 83.29 | 131.54 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.07 | 13.75 | 9.44 | 10.46 | 11.68 | 21.00 | 11.32 | 8.35 | 6.62 | 2.65 |
| EV / EBITDA | — | 321.99 | 738.05 | — | 56.82 | — | 581.76 | 202.73 | 41.23 | — | — |
| EV / EBIT | — | — | — | — | — | — | — | 402.30 | — | — | — |
| EV / FCF | — | 2791.10 | 217.27 | — | — | — | 536.63 | 575.79 | 89.24 | 158.10 | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | 64.6% | 65.3% | 61.6% | 61.5% | 24.2% | 57.1% | 67.6% | 68.5% | 61.2% | 58.1% |
| Operating Margin | — | -1.1% | -8.7% | -30.9% | -7.8% | -29.5% | -6.9% | -2.9% | 18.5% | -9.6% | -59.0% |
| Net Profit Margin | — | -12.6% | -24.5% | -87.6% | -183.4% | -7.5% | 5.5% | -6.1% | 16.5% | -22.8% | -83.6% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | -3.4% | -5.9% | -18.9% | -33.1% | -2.6% | 1.9% | -2.6% | 12.3% | -37.9% | -105.6% |
| ROA | — | -3.0% | -5.0% | -15.4% | -27.9% | -2.3% | 1.6% | -2.4% | 11.3% | -25.1% | -67.7% |
| ROIC | — | -0.3% | -1.7% | -4.8% | -1.1% | -9.4% | -2.5% | -1.3% | 34.5% | -19.7% | -68.4% |
| ROCE | — | -0.3% | -1.9% | -6.0% | -1.3% | -9.6% | -2.2% | -1.2% | 13.5% | -12.1% | -55.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 0.05 | 0.09 | 0.10 | 0.12 | 0.06 | 0.05 | 0.02 | — | — | 0.90 |
| Debt / EBITDA | — | 4.96 | 19.70 | — | 3.11 | — | 6.42 | 0.89 | — | — | — |
| Net Debt / Equity | — | -0.04 | -0.19 | 0.02 | 0.07 | -0.09 | -0.39 | -0.06 | -0.71 | -0.66 | 0.45 |
| Net Debt / EBITDA | — | -4.20 | -42.57 | — | 1.73 | — | -45.68 | -3.33 | -7.66 | — | — |
| Debt / FCF | — | -36.40 | -12.53 | — | — | — | -42.14 | -9.47 | -16.59 | -14.45 | — |
| Interest Coverage | — | -0.40 | -9.92 | -14.15 | -15.54 | -63.19 | -199.28 | 154.00 | -5000.00 | -4.68 | -24.26 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | — | 5.94 | 4.54 | 2.86 | 3.11 | 2.95 | 7.37 | 3.11 | 19.37 | 6.56 | 4.08 |
| Quick Ratio | — | 4.63 | 3.66 | 1.83 | 2.32 | 2.28 | 6.62 | 1.68 | 17.56 | 5.34 | 2.53 |
| Cash Ratio | — | 3.87 | 3.19 | 1.05 | 1.41 | 1.64 | 5.81 | 0.83 | 15.81 | 4.40 | 1.24 |
| Asset Turnover | — | 0.24 | 0.21 | 0.18 | 0.17 | 0.22 | 0.20 | 0.29 | 0.43 | 0.91 | 1.04 |
| Inventory Turnover | — | 1.13 | 0.99 | 2.22 | 0.84 | 3.19 | 1.78 | 0.80 | 1.77 | 2.32 | 1.96 |
| Days Sales Outstanding | — | 30.17 | 40.68 | 89.77 | 162.47 | 71.12 | 60.77 | 71.28 | 56.30 | 33.81 | 52.96 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | 0.2% | 0.1% | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | 0.0% | 0.4% | — | — | — | 0.2% | 0.2% | 0.9% | 0.6% | — |
| Buyback Yield | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.2% | 0.0% | 0.0% |
| Total Shareholder Yield | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 2.4% | 0.1% | 0.0% |
| Shares Outstanding | — | $49M | $46M | $44M | $42M | $39M | $27M | $19M | $16M | $13M | $13M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BLFS stock.
Based on historical data, BioLife Solutions, Inc. is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Earnings quality and margin sustainability
Metrics are mathematically derived from official filings.
Margin Recovery Hinges on Cost Discipline
Gross margin held near 64% in 2026Q2, but operating margin of 6.0% remains thin, reflecting elevated SG&A. According to the latest quarterly data, profitability is improving from a trough but remains vulnerable to cost overruns.
The 2026Q2 operating margin of 6.0% marks a sharp recovery from the -65.5% in 2025Q2, which was distorted by impairment charges. However, the gross margin of 64.2% is slightly below the 67.5% seen in 2025Q4, suggesting that the company has not yet regained full pricing power or cost efficiency. The persistent gap between gross and operating margins indicates that SG&A expenses, which have averaged around $13.5M per quarter, continue to consume a significant portion of revenue. Investors should monitor whether the divestiture of low-margin freezer operations leads to structural operating leverage, as the current operating margin is still far below the gross margin potential.
ROIC Remains Subdued Despite Asset-Light Shift
ROIC was only 0.3% in 2026Q2, up from negative levels a year earlier, but still far below the cost of capital. As reported in the financial statements, the company's return on invested capital is not yet compounding, reflecting the early stage of its strategic pivot.
ROIC of 0.3% in 2026Q2 is a marginal improvement from the -3.8% in 2025Q2, but it remains negligible, indicating that the company is not yet generating meaningful returns on its invested capital. The asset-light model, with minimal capex, should theoretically boost ROIC as revenue scales, but the current level suggests that the media business is still in investment mode. The high goodwill balance of $208.6M, representing 46.6% of total assets, inflates the invested capital base and depresses ROIC. If the company can grow revenue without proportional increases in fixed costs, ROIC could improve, but the current trajectory does not yet show a clear inflection.
Working Capital Cycle Lengthens on Inventory Buildup
Cash conversion cycle extended to 316 days in 2026Q2, driven by inventory days of 306, up from 281 in the prior quarter. Based on the latest balance sheet data, the company is tying up more cash in inventory, which may signal preparation for growth or inefficiency.
The cash conversion cycle of 316 days in 2026Q2 is elevated, primarily due to inventory days of 306, which have increased from 281 in 2026Q1. This suggests that the company is building inventory, possibly in anticipation of higher demand, but it also ties up cash and increases the risk of obsolescence. DSO improved to 38 days from 34 days, indicating better receivables collection, while DPO remained low at 28 days, meaning the company is paying suppliers quickly. The combination of high DIO and low DPO results in a long cash cycle, which could strain liquidity if not managed carefully. Investors should watch whether this inventory buildup translates into revenue growth or becomes a drag on cash flow.
Minimal Debt Masks Off-Balance-Sheet Risks
Debt-to-equity fell to 0.04 in 2026Q2, with total debt of $15.7M, down from $41.0M a year earlier. According to the latest balance sheet, the company has ample headroom, but the high goodwill balance warrants monitoring for potential impairment.
The company's leverage is minimal, with a D/E ratio of 0.04 and interest coverage of 23.12 in 2025Q4, indicating that debt service is not a concern. The reduction in debt from $41.0M to $15.7M over the past year reflects the use of divestiture proceeds to pay down obligations. However, the balance sheet carries $208.6M in goodwill, which could be subject to impairment if the media business underperforms. While the low leverage provides financial flexibility, the company's reliance on intangible assets means that a significant write-down could erode equity. Investors should monitor the sustainability of the media segment's growth to justify the goodwill balance.
Liquidity Buffer Thins Despite High Current Ratio
Current ratio improved to 9.69 in 2026Q2, but cash dropped to $24.0M from $95.4M in 2024Q4. As reported in the balance sheet, the company's liquidity appears adequate, yet the declining cash balance warrants close monitoring.
The current ratio of 9.69 in 2026Q2 is exceptionally high, indicating that current assets far exceed current liabilities. However, this is partly due to the low level of current liabilities, which fell to $27.5M. Cash and cash equivalents have declined significantly from $95.4M in 2024Q4 to $24.0M in 2026Q2, suggesting that the company has been deploying cash for acquisitions or other investments. The quick ratio of 7.14 remains strong, indicating that the company can cover short-term obligations without relying on inventory sales. Under a severe stress scenario, such as a prolonged biotech funding downturn, the company's cash position could be depleted, but the low debt and high current ratio provide a cushion.
P/E Misleads on a Loss-Making, Asset-Light Model
The trailing P/E of -140.28 and forward P/E of 238.41 are not meaningful for a company with volatile earnings. According to the valuation data, EV/EBITDA of 470.96 better captures the market's premium for the media franchise.
The most commonly misapplied ratio for BioLife Solutions is the P/E multiple, given the company's history of losses and one-time gains. The trailing P/E is negative, and the forward P/E of 238.41 implies an unrealistic earnings growth trajectory, especially since the latest EPS beat was driven by a non-operating gain. EV/EBITDA of 470.96 is also extremely high, but it reflects the market's valuation of the company's EBITDA, which is still near breakeven. A more appropriate metric would be EV/Sales, which at 17.81 indicates the premium the market places on the company's revenue growth potential. Investors should focus on the recurring revenue from the media business and the regulatory moat, rather than earnings multiples that are distorted by non-recurring items.